HOME >> BIOLOGY >> NEWS
African-American women less likely to undergo genetic testing than white women

There are large racial disparities in the use of genetic testing for breast and ovarian cancer, according to a study in the April 13 issue of JAMA.

Mutations in the genes BRCA1 or BRCA2 confer a significantly increased risk of breast and ovarian cancer, according to background information in the article. Women with a BRCA1/2 mutation have a lifetime breast cancer risk of 50 percent to 85 percent and a lifetime ovarian cancer risk of 14 percent to 40 percent. Testing for mutations in BRCA1/2 can provide individual information about breast and ovarian cancer risk that may affect decisions about prophylactic surgery, chemoprevention, and screening. Although clinical testing for BRCA1/2 mutations became available in 1996, relatively little is known about the determinants of testing use in the general population, including potential racial differences in utilization.

Katrina Armstrong, M.D., M.S.C.E., of the University of Pennsylvania School of Medicine, Philadelphia, and colleagues conducted a study to assess the association between race and use of genetic counseling for BRCA1/2 testing among women at risk of carrying a BRCA1/2 mutation and to evaluate the potential contributions of cancer risk perception and worry, socioeconomic characteristics and attitudes about genetic testing.

The study, conducted from December 1999 to August 2003, included 408 women with a family history of breast or ovarian cancer, of whom 217 underwent genetic counseling for BRCA1/2 testing (cases) and 191 women did not (controls).

The researchers found that "African American women with a family history of breast or ovarian cancer are much less likely [78 percent less likely] to undergo genetic counseling for BRCA1/2 testing than are white women with a family history of breast or ovarian cancer. Furthermore, this racial disparity is not explained by differences in the probability of carrying a BRCA1/2 mutation, socioeconomic status, cancer risk perception and wo
'"/>

Contact: Olivia Fermano
215-349-5653
JAMA and Archives Journals
12-Apr-2005


Page: 1 2 3

Related biology news :

1. New clue why MS affects African-Americans differently than Caucasians
2. Slow wave activity during sleep is lower in African-Americans than Caucasians
3. OSA symptoms more common among African-American women than Caucasians
4. Survey finds perceived risk of recurrence low in African-American breast cancer survivors
5. African-Americans at increased risk for earlier preterm births
6. Missouris African-American mothers more likely to deliver prematurely
7. African-Americans with prostate cancer more likely to have family history of prostate, breast cancer
8. Genetic variant is associated with higher rate of premature delivery in African-American women
9. Faulty cell cycle checkpoints linked to lung cancer risk in African-Americans
10. Breast cancer risk increased for African-Americans with mitochondrial DNA variant
11. NJIT ranked 9th in the nation for graduating African-American engineers

Post Your Comments:
(Date:10/15/2014)... to bacterial pneumonia in female mice to an enzyme ... are naturally more resistant to respiratory infections than males. ... increased resistance to bacterial pneumonia in female mice is ... They also show that this enzyme is ultimately activated ... , The team, lead by Professor Lester Kobzik at ...
(Date:10/15/2014)... , Oct. 15, 2014   Neurotechnology ... today announced the availability of the VeriLook ... Surveillance 3.0 provides real-time biometric face identification using ... digital surveillance cameras. The new version not only ... differentiates people from objects while they are moving ...
(Date:10/14/2014)... of years since T. rex took its ... scientists is breathing life back into dinosaurs using high-powered ... research has important implications for how dinosaurs used their ... sense of smell and cool their brains. , ... student Jason Bourke, lead author of the new study ...
Breaking Biology News(10 mins):VeriLook Surveillance 3.0 SDK Identifies Faces and Moving Objects, Differentiates Pedestrians from Other Moving Objects in Video Surveillance Systems 2VeriLook Surveillance 3.0 SDK Identifies Faces and Moving Objects, Differentiates Pedestrians from Other Moving Objects in Video Surveillance Systems 3Dinosaur breathing study shows that noses enhanced smelling and cooled brain 2Dinosaur breathing study shows that noses enhanced smelling and cooled brain 3
(Date:10/22/2014)... -- Nuvilex, Inc. (OTCQB: NVLX) – According to the ... living with diabetes, with  that number expected to grow ... for diabetes treatments is approximately $500 billion.  ... pancreatic cancer.  Pancreatic cancer is the fourth most common ... the United States , and according to a ...
(Date:10/22/2014)... and HONG KONG , Oct. 22, ... therapeutics enterprise, announced today that rare disease expert ... vice president, research. Dr. McKew brings more than two ... positions at the National Institutes of Health, Wyeth Research ... Wyeth). Dr. McKew will lead aTyr,s efforts to expand and ...
(Date:10/20/2014)... YORK , Oct. 20, 2014 ... their experimental ZMapp™ antibody therapeutic to fight the ... how difficult and time-consuming the production of pharmaceuticals ... market research publisher said that while some may ... of this compound, those with industry knowledge are ...
(Date:10/20/2014)... PARK, Calif. , Oct. 20, 2014 /PRNewswire/ ... today that the Company has signed a Notice ... of Regenerative Medicine (CIRM), effective October 1, 2014.  ... Clinical Development payments and the release of additional ... million CIRM grant award for clinical development of ...
Breaking Biology Technology:Nuvilex Brief Analyst Report: Thinking Outside the Box by BrokerBank Securities, Inc. 2aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 2aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 3Kalorama: ZMapp Highlights Need For Faster Biopharmaceutical Production 2Kalorama: ZMapp Highlights Need For Faster Biopharmaceutical Production 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 2Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 4
Cached News: